New oral drug combo tested to keep Kids' leukemia at bay after transplant
NCT ID NCT07012044
Summary
This early-stage study aims to find a safe dose and understand the side effects of an oral drug combination called ASTX727, given with a white blood cell booster (filgrastim), in children with high-risk acute myeloid leukemia (AML). The treatment is given as 'maintenance therapy' after a stem cell transplant, with the goal of preventing the cancer from returning. The study will enroll up to 47 children and young adults up to age 21 who are in remission after their transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.